Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 6.24M | 2.83M | 6.42M | 1.48M | 0.00 |
Gross Profit | 6.24M | 2.83M | 6.27M | -544.00K | -1.98M |
EBITDA | -101.45M | -47.82M | -29.56M | -13.09M | -72.96M |
Net Income | -84.97M | -43.55M | -28.48M | -13.11M | -74.94M |
Balance Sheet | |||||
Total Assets | 374.01M | 179.41M | 83.11M | 9.45M | 161.62M |
Cash, Cash Equivalents and Short-Term Investments | 275.24M | 173.72M | 75.49M | 7.64M | 148.84M |
Total Debt | 1.49M | 585.00K | 788.00K | 0.00 | 0.00 |
Total Liabilities | 21.53M | 10.54M | 127.48M | 26.70M | 17.71M |
Stockholders Equity | 352.48M | 168.87M | -44.37M | -17.25M | 143.91M |
Cash Flow | |||||
Free Cash Flow | -78.28M | -36.97M | -29.21M | -9.94M | -64.42M |
Operating Cash Flow | -78.18M | -36.86M | -29.07M | -9.90M | -64.02M |
Investing Cash Flow | -286.81M | 20.25M | -59.82M | -33.00K | -10.63M |
Financing Cash Flow | 255.62M | 133.57M | 96.68M | 14.91M | 67.74M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | $735.83M | ― | -3.40% | ― | 22.68% | 42.45% | |
55 Neutral | $725.40M | ― | -343.83% | ― | 387.20% | 21.00% | |
55 Neutral | $873.33M | ― | -55.12% | ― | ― | -60.26% | |
52 Neutral | $921.46M | ― | -69.21% | ― | -13.76% | 57.73% | |
51 Neutral | $7.38B | 0.36 | -65.54% | 2.37% | 16.37% | 0.39% | |
51 Neutral | $662.17M | ― | -28.73% | ― | 189.31% | 51.03% | |
45 Neutral | $659.89M | ― | -121.50% | ― | ― | -18.75% |
On May 22, 2025, Dianthus Therapeutics, Inc. announced the resignation of Leon O. Moulder, Jr. from its Board of Directors, with Simon Read, Ph.D., appointed as a new Class III director. Dr. Read will also join the Science and Technology Committee and the Nominating and Corporate Governance Committee, receiving compensation in line with the company’s Non-Employee Director Compensation Policy. The company also held its Annual Meeting of Stockholders on the same day, where Marino Garcia and Paula Soteropoulos were elected as Class I directors. Additionally, stockholders approved executive compensation and ratified Deloitte & Touche, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (DNTH) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Dianthus Therapeutics stock, see the DNTH Stock Forecast page.